Login to Your Account

Plexxikon Files for Approval of Highly Touted Melanoma Drug

By Jennifer Boggs

Thursday, May 12, 2011
A mere four and a half years after launching clinical development, Plexxikon Inc. filed marketing applications in the U.S. and Europe for its targeted melanoma drug PLX4032, now known as vemurafenib.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription